Author: Jennifer C.E Lane; James Weaver; Kristin Kostka; Talita Duarte-Salles; Maria Tereza F. Abrahao; Heba Alghoul; Osaid Alser; Thamir M Alshammari; Patricia Biedermann; Edward Burn; Paula Casajust; Mitch Conover; Aedin C. Culhane; Alexander Davydov; Scott L. DuVall; Dmitry Dymshyts; Sergio Fernández Bertolín; Kristina Fišter; Jill Hardin; Laura Hester; George Hripcsak; Seamus Kent; Sajan Khosla; Spyros Kolovos; Christophe G. Lambert; Johan ver der Lei; Ajit A. Londhe; Kristine E. Lynch; Rupa Makadia; Andrea V. Margulis; Michael E. Matheny; Paras Mehta; Daniel R. Morales; Henry Morgan-Stewart; Mees Mosseveld; Danielle Newby; Fredrik Nyberg; Anna Ostropolets; Rae Woong Park; Albert Prats-Uribe; Gowtham A. Rao; Christian Reich; Jenna Reps; Peter Rijnbeek; Selva Muthu Kumaran Sathappan; Martijn Schuemie; Sarah Seager; Anthony Sena; Azza Shoaibi; Matthew Spotnitz; Marc A. Suchard; Joel Swerdel; Carmen Olga Torre; David Vizcaya; Haini Wen; Marcel de Wilde; Seng Chan You; Lin Zhang; Oleg Zhuk; Patrick Ryan; Daniel Prieto-Alhambra
Title: Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study Document date: 2020_4_10
ID: 2hbcbvt6_17
Snippet: The study period started from 01/09/2000 and ended at the latest available date for all data sources in 2020. Follow-up for each of the cohorts started at an index date defined by the first dispensing or prescription of the target/comparator drug as described in the cohort definitions (Supplementary Table 2 .1). Two periods were considered to define time-at-risk. First, for an intention-to-treat analysis, followup started one day after the inde.....
Document: The study period started from 01/09/2000 and ended at the latest available date for all data sources in 2020. Follow-up for each of the cohorts started at an index date defined by the first dispensing or prescription of the target/comparator drug as described in the cohort definitions (Supplementary Table 2 .1). Two periods were considered to define time-at-risk. First, for an intention-to-treat analysis, followup started one day after the index date and continued up until the first of: outcome of interest, loss to follow-up, or 30 days after the index date to resemble the likely duration of COVID-19 treatment regimens. 23 Secondly, for an on-treatment analysis, follow-up started one day after the index date and continued until the earliest of: outcome of interest, loss to follow-up, or discontinuation, with an added . CC-BY-NC 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- available date and index date: 1
- available date and interest outcome: 1
- available date and International license: 1, 2
- cc NC International license and day start: 1
- cc NC International license and Follow cohort: 1, 2
- cc NC International license and index date: 1, 2
- cc NC International license and interest outcome: 1
- cc NC International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cc NC International license and likely duration: 1
- day start and follow day start: 1
- day start and interest outcome: 1
- day start and International license: 1, 2
- Follow cohort and index date: 1
- Follow cohort and International license: 1, 2
- follow loss and interest outcome: 1, 2
- index date and interest outcome: 1, 2, 3
- index date and International license: 1, 2, 3
- International license and likely duration: 1
Co phrase search for related documents, hyperlinks ordered by date